TRASYLOL, AN ANTI-BLEEDING DRUG ADMINISTERED DURING OPEN HEART SURGERY, LINKED TO KIDNEY DAMAGE AND OTHER HEALTH PROBLEMS
Trasylol, also known by the name aprotinin, is an antifibrinolytic drug manufactured by Bayer Pharmaceuticals which is used to reduce blood loss during cardiac bypass heart surgery. In 2007, the FDA announced that Bayer was suspending all marketing for Trasylol after a series of studies were released beginning in January 2006 demonstrating increased safety risks associated with Trasylol use in patients, including increased risk of kidney problems, stroke, and mortality. Trasylol has not been placed back on the market. Because Trasylol is administered in surgery, many patients may not know that they ever received the drug.
If you or someone you know has experienced kidney dysfunction requiring dialysis or kidney failure following heart surgery, or has experienced stroke or death following heart surgery, please contact our law offices. We can obtain a copy of your medical records to verify whether Trasylol was administered during surgery, and help you understand your legal rights.
Contact our firm if you are interested in learning more about this investigation.